Atharva BioSciences - leaders in innovative Molecular Diagnostics

Our Lab is for you   

Diagnostic Testing Infectious Diseases
  Overview of Virus About the Assay Collection & Shipping Abstracts & Publications


Test ID 4500 EBV qPCR
Description
Quantitative, Real Time DNA PCR for viral load monitoring.

Procedure

Extraction of viral DNA from cell-free plasma; amplification and detection of Epstein-Barr Virus DNA using Real Time, quantitative, polymerase chain reaction (TaqMan® ) technique.

Real Time PCR
Linear Range
Real Time PCR technology allows us to detect less than 10 copies and as many as 1 x 107 copies.
Specimens Whole Blood: 3-5 mls collected in an EDTA tube.
Other: (CSF / lung / bone marrow aspirate, urine, tissue, etc.): please inquire.
Specificity The primers used in this assay are specific for EBV based on similarity search algorithm (BLAST). The assay was also tested against HSV 1, HSV 2, CMV, HHV-6A, HHV-6B and BK viruses with no cross reactivity detected.
Assay
Results Range

The results range of the assay is 100 copies/ml to 1 x 1010 copies/ml.
Clinical Validation This assay can be useful for following plasma viral load in a number of clinical situations. The most important such condition is post transplant EBV infection, or reactivation, which can lead to lymphoproliferative disease or lymphoma.
Post-transplant lymphoproliferative disease (PTLD) is an uncommon but important cause of morbidity and mortality in organ transplant recipients. PTLD results from uncontrolled EBV induced proliferation of B cells in the setting of immunosuppression. Virus found in plasma may be indicative of active infection.1 Multiple clinical studies have shown cell-free plasma PCR to be predictive of EBV related disease including PTLD.1 In addition to potentially serving as an adjunct to the early diagnosis of PTLD2, quantitation of EBV DNA in plasma may be used to identify patients at risk for developing PTLD.2
Turn-around-Time Within 24 hours of receipt of specimen
CLIA certified
lab and Disclaimer
This assay was developed and the performance characteristics were determined at ViraCor. This test is not FDA approved; however, the test is performed in a CLIA certified laboratory and approval from the FDA is not required for the performance of this test.

PCR tests are performed pursuant to a license agreement with Roche Molecular Systems, Inc.

References:

  1. Wagner, Hans-Joachim, et al. Patients at Risk for Development of Posttransplant
    Lymphoproliferative Disorder: Plasma Versus Peripheral Blood Mononuclear Cells as Material
    for Quantification of Epstein-Barr Viral Load by Using Real Time Quantitative Polymerase
    Chain Reaction. Transplantation, September 27 2001; Vol. 72, 1012-1019.
  2. Limaye, Ajit, et al. Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders. Journal of Clinical Microbiology, April 1999; Vol. 37, 1113-1116.


Atharva BioSciences
ISO 9001:2000 Certified
B-4/233, Safdarjung Enclave, New Delhi 110 029  Telephone: (+91-11) 6546 7029   Fax: (+91-11) 4135 4257 
email: contact@atharvasciences.com
© Copyright 2008. All Rights Reserved.